BKD Stock Overview
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bruker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$76.72 |
| 52 Week High | US$86.50 |
| 52 Week Low | US$51.50 |
| Beta | 1.18 |
| 1 Month Change | -11.31% |
| 3 Month Change | 17.13% |
| 1 Year Change | 9.60% |
| 3 Year Change | 33.43% |
| 5 Year Change | 126.41% |
| Change since IPO | 164.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| BKD | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.3% | -4.6% | 1.8% |
| 1Y | 9.6% | -8.0% | 2.2% |
Return vs Industry: BKD exceeded the German Life Sciences industry which returned -8% over the past year.
Return vs Market: BKD exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| BKD volatility | |
|---|---|
| BKD Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BKD has not had significant price volatility in the past 3 months.
Volatility Over Time: BKD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 9,707 | Frank Laukien | www.bruker.com |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.
Bruker Corporation Fundamentals Summary
| BKD fundamental statistics | |
|---|---|
| Market cap | €11.20b |
| Earnings (TTM) | €399.18m |
| Revenue (TTM) | €2.77b |
28.0x
P/E Ratio4.0x
P/S RatioIs BKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BKD income statement (TTM) | |
|---|---|
| Revenue | US$2.96b |
| Cost of Revenue | US$1.45b |
| Gross Profit | US$1.52b |
| Other Expenses | US$1.09b |
| Earnings | US$427.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.94 |
| Gross Margin | 51.25% |
| Net Profit Margin | 14.41% |
| Debt/Equity Ratio | 87.3% |
How did BKD perform over the long term?
See historical performance and comparison